Company Description
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
The company’s CELsignia diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the related targeted therapy for the treatment.
Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer.
It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib.
The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
| Country | United States |
| Founded | 2011 |
| IPO Date | Sep 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Brian Sullivan |
Contact Details
Address: 16305–36th Avenue North, Suite 100 Minneapolis, Minnesota 55446 United States | |
| Phone | 763 392 0767 |
| Website | celcuity.com |
Stock Details
| Ticker Symbol | CELC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001603454 |
| CUSIP Number | 15102K100 |
| ISIN Number | US15102K1007 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Brian F. Sullivan | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Lance G. Laing Ph.D. | Co-Founder, Chief Science Officer, Vice President, Secretary and Director |
| Vicky Hahne CPA | Chief Financial Officer |
| Brent Eilefson | General Counsel |
| Sheri Smith | Acting Head of Clinical Operations |
| Igor Gorbatchevsky M.D. | Chief Medical Officer |
| Eldon C. Mayer III, M.B.A. | Chief Commercial Officer |
| Dr. Charlotte Moser M.B.A., M.D., M.Sc., Ph.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | SCHEDULE 13G/A | Filing |
| Feb 4, 2025 | SCHEDULE 13G | Filing |
| Dec 6, 2024 | 8-K | Current Report |
| Dec 6, 2024 | 424B5 | Filing |
| Dec 2, 2024 | EFFECT | Notice of Effectiveness |